搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
来自MSN
2 分钟
Denali Calling: Testing the Iridium GO! Satellite Hotspot on North America’s Tallest Mountain
We huddled in the cook tent at 14,000 feet on the West Buttress of Denali as temperatures plummeted to near 0 degrees F. Do ...
6 天
探秘好莱坞明星的传奇座驾:YUKON DENALI
YUKON DENALI 以其霸气的外观、强大的性能和极致的奢华,成为了好莱坞明星们的传奇座驾。它不仅是一款交通工具,更是一种身份与品味的象征。无论是在繁华的都市街头,还是在星光熠熠的红毯上,YUKON DENALI ...
5 天
Denali Therapeutics首席医疗官Carole Ho出售价值308,290美元的股票
根据提交给美国证券交易委员会的文件显示,Denali Therapeutics Inc. (NASDAQ:DNLI)的首席医疗官Carole Ho最近出售了公司的普通股。1月6日和7日,Ho总共出售了15,162股,获得308,290美元。售价在每股20.22美元至20.81美元之间。根据 InvestingPro ...
10 小时
Denali Therapeutics (DNLI) Receives a Buy from TD Cowen
In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Denali Therapeutics (DNLI – Research Report). The company’s ...
7 天
Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment
Denali Therapeutics shares reversed higher on Tuesday after the drugmaker's ALS treatment failed in a six-month study.
The Manual on MSN
4 天
Experience Denali like never before with exclusive fly-in wilderness travel
AdventureSmith Explorations offers exclusive fly-in wilderness travel options that take you straight into the heart of Denali ...
7 天
Denali股票维持买入评级,分析师强调2025年可能获批亨特综合征治疗药物
分析师评论了Denali最近的股价下跌,将其归因于更广泛的市场趋势,而非公司特定消息。Denali的股价回调反映了XBI生物技术指数的走势,被认为是整体投资组合定位转变的一部分,在高利率环境下,较大的基金可能减少了生物技术领域的敞口。
FierceBiotech
6 天
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
STAT
6 天
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
BioSpace
7 天
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈